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ABSTRACT
Introduction: Inflammation, insulin resistance,
and oxidative stress (OS) are among the
mechanisms that have been implicated in the
pathogenesis of essential hypertension (EH).
Peripheral polymorphonuclear leukocytes
(PMNLs) are primed in EH patients, releasing
uncontrolled superoxide anions contributing to
OS in these patients. PMNL priming correlates
with insulin resistance and PMNL intracellular
calcium ([Ca2?]i). Recent studies have attributed
additional anti-ischemic and antioxidative
characteristics to the antihypertensive drug,
lercanidipine, a third-generation calcium-
channel blocker. The purpose of this study was
to evaluate the possible nontraditional effect of
2 months of lercanidipine treatment on insulin
resistance and on PMNL-related inflammation
in EH patients.
Methods: Non-smoking EH patients with
untreated mild-to-moderate high blood
pressure (BP) were included. Low-grade
inflammation was reflected by PMNL apoptosis
and by white blood cell (WBC) and PMNL
counts. Systemic inflammation was measured
by plasma fibrinogen, C-reactive protein (CRP),
and transferrin and albumin levels. Fasting
serum insulin levels served as a marker of
insulin resistance.
Results: Two months of lercanidipine
treatment showed a significant decrease in BP,
WBC, and PMNL counts, PMNL apoptosis, CRP,
and serum insulin levels, and a significant
increase in serum albumin levels. Rates of
superoxide release from PMNLs, WBC and
PMNL counts, and insulin levels positively
correlated with mean arterial BP values.
Conclusion: The use of lercanidipine can be
favorable in EH patients due to its combined
anti-PMNL priming and anti-inflammatory
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effects, in addition to its antihypertensive
characteristics.
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INTRODUCTION
Essential hypertension (EH) is a substantial public
health problem, affecting 25% of the adult
population in industrialized societies [1]. This
multifactorial and multigenetic disorder is a
major risk factor for many common causes of
mortality and morbidity including stroke,
myocardial infarction, congestive heart failure,
and end-stage renal disease [2]. Insulin resistance is
seen in more than half of patients with EH [3].
Despite the important role of EH as a cause of
disease, itspathogenesis remains largelyunknown.
Abnormalities in endothelial function and
morphology appear to play a central role in
the pathogenesis of hypertension-related
atherosclerosis [4]. Among the mechanisms
causing endothelial dysfunction that have
been recently implicated in EH is oxidative
stress (OS), which may impair endothelium-
dependent vasodilatation, inflammation, and
insulin resistance [5]. Primed peripheral
polymorphonuclear leukocytes (PMNLs) are
one of the main types of inflammatory cells;
once activated, primed PMNLs release reactive
oxygen species (ROS), contributing to OS, low-
grade inflammation, endothelial damage, and
atherosclerosis in the long term [6, 7]. Recently,
the authors have previously reported that
PMNLs contribute to the OS and inflammation
in correlation with insulin resistance and PMNL
intracellular calcium ([Ca2?]i) in EH [8, 9]. In
addition, the authors have recently implicated
PMNL priming as a key mediator of low-grade
inflammation and OS associated with renal
failure [10]; thus, constituting a common
denominator in clinical states, such as
hypertension, renal failure, and diabetes, and
in cigarette smoking, which is known to be
associated with endothelial dysfunction and
accelerated atherosclerosis [8–12].
The long-acting calcium channel blockers
(CCB), widely used in the clinical setting,
have been shown to prevent atherosclerosis
[13–15], among which amlodipine has an
antioxidative action in vivo [16]. In the current
study, the authors examined the effects
of monotherapy using lercanidipine, a
vasoselective dihydropyridine CCB that causes
systemic vasodilatation by blocking the influx of
calcium ions through L-type calcium channels
in cell membranes. As a highly lipophilic drug,
lercanidipine has a slower onset, longer duration
of action, and fewer adverse effects than a
number of other CCB [17]. In well-controlled
clinical studies, once-daily administration of 10
or 20 mg lercanidipine effectively reduced blood
pressure compared with placebo in patients with
mild-to-moderate hypertension without
affecting heart rate [18]. However, there are no
precedent studies that demonstrate the various
effects of this drug on systemic and PMNL-
related inflammation, and on insulin resistance
over a period of 2 months of treatment. Thus,
the objective of the present study was to




Fifteen untreated EH patients (12 males/3
females) with mild-to-moderate hypertension
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(age range 20–65 years) and 15 age and gender-
matched healthy controls (NCs) were enrolled
in this prospective study. Inclusion criteria of
the EH group were: sitting diastolic blood
pressure (DBP) [90 mmHg (average of three
outpatient visits); sitting systolic blood pressure
(SBP) [140 mmHg (average as above); body
mass index \30 kg/m2; no evidence of target
organ damage and systemic diseases supported
by microalbumin/creatinine ratio, fundus
examination, echocardiogram test, and kidney
function tests. Subjects with evidence of acute
or chronic infection, inflammation, receiving
medication, vitamins, or antioxidants,
smoking, and secondary causes of
hypertension were excluded. The selection of
all participants was based upon a clinical
examination and laboratory confirmation. All
subjects had normal fasting ([14 h), serum
cholesterol (\205/230 mg/dL), triglycerides
(\158 mg/dL), and glucose levels with normal
kidney and liver function (Table 1). The study
was approved by signing an informed consent
for blood sampling approved by the
institutional committee in accordance with
the Declaration of Helsinki.
Blood was drawn in the morning after an
overnight fast from all EH patients and NC
subjects for the determination of biochemical
and hematological parameters, and for PMNL
Table 1 The changes in measurements of EH patients
NC Untreated EH 1-month treatment 2-month treatment P value
Fundus Negative Negative Negative Negative
SBP (mmHg) 120 ± 3.0a 162 ± 4.0 146 ± 3.0a 143 ± 3.0a \0.01
DBP (mmHg) 69 ± 2.0a 100 ± 1.0 89 ± 3.0a 87 ± 2.0a \0.01
MAP (mmHg) 86 ± 2.0a 120 ± 2.0 108 ± 2.0a 107 ± 2.0a \0.01
Cholesterol (mg/dL) 205 ± 1.7 230 ± 9.3 225 ± 13.2 226 ± 15.6 NS
Triglycerides (mg/dL) 120 ± 3.2 158 ± 26.0 149 ± 19.2 130 ± 23.7 NS
HDL (mg/dL) 58 ± 0.7 42.8 ± 1.4 40.4 ± 2.0 39.2 ± 3.3 NS
LDL (mg/dL) 114 ± 1.3 155 ± 6.6 155 ± 10.8 161 ± 11.8 NS
Glucose (mg/dL) 94 ± 1.9 89.1 ± 4.5 98.4 ± 3.4 100.8 ± 5.0 NS
Creatinine (mg/dL) 0.93 ± 0.02 0.96 ± 0.03 0.98 ± 0.04 0.95 ± 0.04 NS
ALT (U/L) 20 ± 0.5 38.0 ± 6.2 30.7 ± 6.3 38.4 ± 5.0 NS
AST (U/L) 19.6 ± 0.3 26.6 ± 3.3 25.4 ± 5.1 24.0 ± 3.6 NS
ALP (U/L) 75 ± 6.1 87.8 ± 5.5 83.7 ± 5.4 81.9 ± 5.0 NS
LDH (U/L) 283 ± 1.9 294 ± 11.9 311 ± 17.0 313 ± 13.0 NS
Hb (g/dL) 14.3 ± 0.1 14.7 ± 0.3 14.6 ± 0.3 14.7 ± 0.2 NS
Insulin (U/mL) 8.4 ± 0.9a 15.1 ± 1.1 16.4 ± 4.1 10.1 ± 1.1a \0.01
Values are mean ± SEM
ALP alkaline phosphatase, ALT alanine transaminase, AST aspartate aminotransferase, DBP diastolic blood pressure, EH
essential hypertension, Hb hemoglobin, HDL high-density lipoprotein, LDH lactate dehydrogenase, LDL low-density
lipoprotein, MAP mean arterial pressure, NC normal control, NS not signiﬁcant, SBP systolic blood pressure
a Versus untreated EH patients
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isolation. Blood was drawn from EH patients
before and following treatment with 10 mg/day
lercanidipine for 1 and 2 months.
PMNL isolation was carried out from a 20-mL
heparinized blood sample as previously
described [10, 19]. The separated PMNLs
([98% pure, approximately 107 cells per
isolation) were resuspended in phosphate-
buffered saline (PBS) containing 0.1% glucose.
Sera and plasma were frozen at -20C for
determining the clinical and biochemical
characteristics of the participants, and for
systemic inflammation parameters.
PMNL Priming
Rate of Superoxide Release
The measurements of the rate of superoxide
release are based on superoxide dismutase (SOD)
inhibitable reduction of 80 lM cytochrome C
(Sigma, St. Louis, MO, USA) to its ferrous form
[20]. The rate of superoxide release was
monitored from 106 separated PMNLs, after
stimulation with 0.32 9 10-7 M phorbol
12-myristate 13-acetate (PMA; Sigma, St. Louis,
MO, USA), at 22C for 50 min. This parameter
was used as a measure of PMNL priming.
PMNL-Derived Inflammation
WBC and PMNL Counts
Counts of WBC and PMNLs from blood drawn
in ethylenediaminetetraacetic acid (EDTA) were
performed by an automated cell counter
(Coulter STKS Analyzer, Coulter Corporation,
Miami, FL, USA) and used as a measure of low-
grade inflammation.
Analysis of Apoptotic PMNLs
Apoptosis was analyzed in whole blood from EH
patients and NC subjects of each group by flow
cytometry according to Kuypers et al. [21]. Blood
samples were assayed for apoptosis after lysis of
red blood cells by Q PREPTM (Beckman Coulter,
Inc., Galway, Ireland) and incubated with
fluorescein isothiocyanate (FITC)-labeled
monoclonal antibodies using the Annexin V
kit (Bender MedSystems, Vienna, Austria).
PMNLs were defined by forward scatter/side
scatter and by R-phycoerythrin (PE)-labeled
monoclonal anti-CD16.
Systemic Inflammation
Measurement of Plasma Fibrinogen
Fibrinogen was measured in a Cobas Mira plus
instrument (Roche, Mannheim, Germany), in
all plasma samples using the K-Assay kit
(Kamiya Biomedical Company, Seattle, WA,
USA).
Measurement of C-Reactive Protein,
Transferrin, and Albumin
C-reactive protein (CRP), transferrin, and albumin
were routinely assayed in the biochemistry lab
using a Hitachi 917 Automatic Analyzer (Roche
Diagnostics, Mannheim, Germany) in separated
sera obtained from all EH patients and NC subjects
after an overnight fast.
Insulin as a Marker of Insulin Resistance
Fasting serum insulin levels served as a measure
for insulin resistance, and were measured using
an electrochemiluminescence immunoassay kit
(Roche Diagnostics, Mannheim, Germany).




Data are expressed as mean ± SEM. Differences
in mean values were tested by two-way analysis
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of variance (ANOVA) and by the Bonferroni
multiple comparison test, using Prism version
3.0 statistical software (GraphPad software, San
Diego, CA, USA). Correlations between different
study parameters were performed using Pearson




Table 1 summarizes the clinical and
biochemical characteristics of the participants.
All studied groups of patients showed similar
serum cholesterol, serum creatinine, serum
triglycerides, liver enzymes, and serum glucose
levels, without showing target organ damage.
Most traditional risk factors were similar during
the lercanidipine treatment period. Blood
pressure values, namely DBP, SBP, and mean
arterial pressure (MAP) decreased significantly
following 1 and 2 months of lercanidipine
treatment (Table 1).
PMNL Priming
Rate of Superoxide Release
Significantly faster rates of superoxide release
from PMA-stimulated PMNLs were found in EH
patients before and following 2 months of
lercanidipine treatment (Table 2), as compared
to NCs (18.2 ± 1.2 nmol/106 cells/10 min),
reflecting a higher priming state in these
groups (EH). Two months of treatment
reflected a slight, though significant, decrease
in the rate of superoxide release from PMA-
stimulated PMNLs (Table 2).
PMNL-Derived Inflammation
WBC and PMNL Counts
EH patients had significantly higher numbers of
WBC and PMNLs (Table 2), as compared to NC
subjects (7.2 ± 0.1 and 3.9 ± 0.2 9 109 cells/mL,








WBC 9109 7.2 ± 0.1 7.8 ± 0.5 7.4 ± 0.4 7.1 ± 0.2a \0.05
PMNL 9109 3.9 ± 0.2a 4.8 ± 0.4 4.4 ± 0.4 4.2 ± 0.2a \0.05
PMNL apoptosis (%) 2.8 ± 0.7a 15.4 ± 1.8 11.5 ± 2.0 7.2 ± 1.0a \0.05
Rate of superoxide release (nmol/106 cells/10 min) 18.2 ± 1.2 29.0 ± 1.6 31.7 ± 1.3 27.5 ± 1.3b \0.05
Fibrinogen (mg/dL) 289 ± 12.0a 393 ± 48.0 387 ± 34.0 367 ± 30.0 NS
Albumin (g/dL) 4.6 ± 0.05a 4.5 ± 0.06 4.6 ± 0.07 4.6 ± 0.05a \0.05
Transferrin (g/dL) 273 ± 5.0a 288 ± 8.0 276 ± 6.0 274 ± 7.0 NS
CRP (mg/L) 1.46 ± 0.1a 3.91 ± 0.9 3.04 ± 0.9 1.67 ± 0.6a \0.05
Values are mean ± SEM
CRP C-reactive protein, EH essential hypertension, NC normal control, NS not signiﬁcant, PMNL peripheral
polymorphonuclear leukocytes, WBC white blood cells
a Versus untreated EH patients
b Versus EH patients treated with lercanidipine for 1 month
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respectively), although all values fell within the
upper quartile of the normal range. Two
months of lercanidipine treatment
significantly reduced WBC and PMNL counts
(Table 2).
Percentage of Apoptotic PMNLs
The percentage of apoptotic PMNLs, assayed
immediately after blood withdrawal in whole
blood, was significantly higher in EH group of
patients (Fig. 1), as compared to NCs
(2.8% ± 0.7%). One month of lercanidipine
treatment significantly reduced the percentage
of apoptotic PMNLs, a reduction that was
further amplified after 2 months of treatment.
Systemic Inflammation
Measurement of Plasma Fibrinogen
Plasma fibrinogen levels fell within the upper
quartile of the normal range and were higher
than the levels of the NC subjects (289 ± 12 mg/
dL). A slight nonsignificant reduction in plasma
fibrinogen levels was found after 2 months of
lercanidipine treatment (Table 2).
Measurement of CRP, Albumin,
and Transferrin
Significantly decreased serum CRP levels were
shown after 2 months of lercanidipine
treatment compared with untreated EH
(1.46 ± 0.1 mg/L; Fig. 2). Increased serum
albumin levels were found in NCs and treated
EH patients compared with untreated EH
patients, although all fell within normal range.
In addition, a significant change was found in
the serum transferrin levels of NCs compared
with untreated EH (Table 2).
Insulin as a Marker of Insulin Resistance
Fasting serum insulin levels served as a measure
of insulin resistance [9]. Figure 3 shows a
significant decrease of serum insulin levels
after 2 months of lercanidipine treatment,
although levels were still higher than levels in
NCs (8.4 ± 0.9 lU/mL) after 2 months of
treatment. It has to be emphasized that in
these mild-to-moderate untreated EH patients,
Fig. 1 PMNL apoptosis in whole blood of EH patients
before and following 1 and 2 months of lercanidipine
treatment. Data are mean ± SEM. a P = 0.001 versus
PMNLs from untreated EH patients. EH essential
hypertension, PMNL peripheral polymorphonuclear
leukocytes
Fig. 2 Serum CRP levels in EH patients before and
following 1 and 2 months of lercanidipine treatment. Data
are mean ± SEM. a P = 0.001 versus sera from untreated
EH patients. CRP C-reactive protein, EH essential
hypertension
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most serum insulin levels were within the
normal range, although in the upper quartile.
PMNL Priming and Inflammation
in Relation to MAP
PMNL priming expressed by the rate of
superoxide release in NCs and EH patients
(treated and untreated with lercanidipine) was
positively correlated with MAP: r = 0.43,
P\0.001 (n = 106; Fig. 4a); the higher the
blood pressure parameter, the higher the
superoxide release. The WBC counts from NCs
and EH patients (treated and untreated with
lercanidipine) were positively correlated with
MAP: r = 0.25, P = 0.009 (n = 109; Fig. 4b). The
peripheral PMNL counts from NCs and EH
patients (treated and untreated with
lercanidipine) were also positively correlated
with MAP: r = 0.2, P = 0.04 (n = 109; Fig. 4c).
Systemic Inflammation Parameters
in Relation to MAP
Fibrinogen and CRP, the accepted positive
systemic inflammation markers, determined in
NCs and EH patients (treated and untreated
with lercanidipine), correlated with MAP.
Plasma fibrinogen levels positively correlated
with MAP: r = 0.27, P = 0.007 (n = 101; Fig. 5a).
However, no correlation could be found
between serum CRP levels and MAP: r = 0.05,
P = 0.6 (n = 109; Fig. 5b).
Fig. 3 Serum insulin levels in EH patients before and
following 1 and 2 months of lercanidipine treatment. Data
are mean ± SEM. a P = 0.004 versus sera from untreated
EH patients. EH essential hypertension
Fig. 4 Correlation between the rates of superoxide release
from separated PMA-stimulated PMNLs and MAP (a);
correlation between WBC counts and MAP (b);
correlation between PMNL counts and MAP (c). Data
refer to values from all EH patients (treated and untreated)
and NC subjects (a; n = 106, b and c; n = 109). EH
essential hypertension, MAP mean arterial pressure, NC
normal control, PMA phorbol 12-myristate 13-acetate,
PMNL peripheral polymorphonuclear leukocytes, WBC
white blood cells
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Serum Insulin Levels in Relation to MAP
Fasting serum insulin levels, serving as a
measure for insulin resistance, positively
correlated with MAP: r = 0.36, P = 0.0001
(n = 110; Fig. 6).
DISCUSSION
The present study evaluates the role of
lercanidipine, a dihydropyridine CCB, in mild-
to-moderate hypertensive patients and its
nontraditional effects on PMNL priming,
PMNL-related inflammation, systemic
inflammation markers, and insulin resistance.
The authors’ previous studies showed that
EH is accompanied by a primed state of PMNLs,
inducing OS and inflammation [8, 9]. The
authors have defined PMNL priming as a
common denominator in other clinical states,
such as hypertension, diabetes, and in cigarette
smoking, which is known to be associated with
endothelial dysfunction, accelerated
atherosclerosis, and increased prevalence of
cardiovascular morbidity and mortality [8, 9,
11, 12]. In addition, the authors have recently
shown that PMNL priming constitutes a key
mediator of low-grade inflammation and OS
associated with renal failure [10]. In the present
study, the authors examined the PMNL-related
priming and inflammation parameters from EH
patients before and after 1 and 2 months of
antihypertensive treatment.
A novel, interesting observation was the
significantly higher percentage of apoptotic
PMNL in EH patients as compared to NC, and
the significant decrease in the percentage of
apoptotic PMNLs after only 1 month of
treatment with lercanidipine; a reduction
further amplified after 2 months of treatment.
PMNL apoptosis has already been shown to be
associated with low-grade inflammation
parameters, along with WBC and PMNL counts
Fig. 5 Correlation between plasma ﬁbrinogen levels and
MAP (a); correlation between serum CRP levels and MAP
(b). Data refer to values from all EH patients (treated and
untreated) and NC subjects. (a; n = 101, b; n = 109).
CRP C-reactive patients, EH essential hypertension, MAP
mean arterial pressure, NC normal control
Fig. 6 Correlation between serum insulin levels and
MAP. Data refer to values from all EH patients (treated
and untreated) and NC subjects (n = 110). EH essential
hypertension, MAP mean arterial pressure, NC normal
control
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[10], which constitute a mortality predictor in
hemodialysis patients [22, 23], and as a predictor
for developing chronic kidney disease [24]. In
the present study, WBC and PMNL counts were
also higher in EH patients, and declined
significantly after treatment with lercanidipine,
exhibiting a reduction in the PMNL-related low-
grade inflammation.
In parallel, other systemic inflammation
markers, such as CRP, fibrinogen, transferrin,
and albumin were also assessed. Serum albumin
is a negative acute-phase protein whose low
level is attributed to inflammation [25];
although in the normal range, the authors
showed a significant increase following
lercanidipine treatment. Th reduction in
fibrinogen was slight and nonsignificant, and
transferrin levels did not change, possibly due
to the relatively small number of the patients.
An interesting observation from the present
study is the significant decrease in CRP level
during treatment with lercanidipine to low
levels as observed in NC, which are predictive
of reduced cardiovascular risk. Numerous
studies have demonstrated that elevated CRP
levels and upper quartile of normal levels are
highly predictive of an increased incidence of
cardiovascular events in healthy males and
females [26–28]. The low-grade inflammation
derived from PMNL priming does not correlate
with CRP. These findings imply that different
processes are involved in inflammation, which
need to be further clarified.
In the present study, lercanidipine treatment
significantly lowered fasting serum insulin
levels. EH patients have higher plasma insulin
levels in response to glucose load, whether
obese or of normal body weight [29]. This
hyperinsulinemia is a consequence of
resistance to the effects of insulin on
peripheral glucose utilization and to decreased
hepatic uptake of insulin [30]. Elevated [Ca2?]i
has been described in various cells in insulin-
resistant states, such as uremia, diabetes, and
EH [31–33]. The present authors have
previously showed a link between PMNL
[Ca2?]i, plasma insulin in EH, and elevated
[Ca2?]i, contributing to OS and inflammation
[9]. Furthermore, the reported correlation of
individual blood pressure with both PMNL
[Ca2?]i and plasma insulin levels, together
with the fact that elevated PMNL [Ca2?]i
mediates PMNL priming, suggest that elevated
PMNL [Ca2?]i and insulin are involved in the
pathogenesis of hypertension-induced vascular
injury in EH. The cause of slight increases in
glucose levels of the normal upper limit after
2 months’ treatment is not exactly known, but
could be related to high activity of the enzyme
hormone-sensitive lipase due to low
concentrations of insulin [34]. However,
follow-up after several months showed that
diabetes or prediabetes did not develop in any
of the participant patients.
In the present study, the authors showed a
correlation between MAP and PMNL-related
priming, and inflammation parameters. A
significant link between blood pressure and
ROS formation by PMNLs has been observed
by Yasunari et al. [35]. In addition, Yasunari
et al. reported inhibition of ROS formation by
PMNLs after treatment with benidipine, a long-
acting CCB, which can be attributed in part to
the decreased blood pressure. However,
Yasunari et al. [35] did not completely rule out
the possibility that the drug itself served as an
antioxidative agent. In the present study,
lercanidipine, a long-acting CCB, was chosen
for treating hypertension because it shows high
efficacy in mild-to-moderate hypertension and
has a low incidence of adverse effects and good
tolerability by most patients. Several studies
have demonstrated that lercanidipine shows
anti-ischemic and antioxidative effects [18,
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36–39] due to its ability to inhibit the growth of
smooth muscle cells and their migration to the
blood vessel wall, indicating a possible anti-
atherosclerotic effect of the drug [37, 40]; thus,
may be useful in the treatment of insulin-
resistant hypertensive patients.
The small sample size was not randomized or
blinded, as the authors had to select appropriate
patients based on the inclusion criteria (no
smoking and no other chronic illness, and
without any hypertensive treatment that may
cause a change in inflammatory markers).
However, it was not simple to find patients
who meet these inclusion criteria. Other
limitations include the control group, who
were also the untreated EH patients at
baseline. Furthermore, the examined drug has
not yet been tested in vitro; it has only been
tested in small sample studies whose positive
results have not yet been published.
In summary, lercanidipine, in addition to its
effect as an antihypertensive drug, carries anti-
inflammatory features improving most
inflammation markers, systemic and PMNL-
related, and can improve insulin sensitivity.
The amelioration in the inflammatory
parameters can be attributed, in part, to the
decrease in blood pressure. Future, in vitro
experiments are needed to find a direct effect
of lercanidipine on PMNL-contributed low-
grade inflammation.
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